Promising Results of Baxdrostat in Managing High Blood Pressure and Kidney Disease

The FigHTN Phase 2 clinical trial revealed that baxdrostat, an aldosterone production inhibitor, reduced systolic blood pressure by 5% and decreased urine albumin loss by 55% in individuals with chronic kidney disease and uncontrolled hypertension. These findings suggest baxdrostat's potential to delay kidney disease progression and improve long-term health outcomes, offering a promising solution for this at-risk population.